Market Cap | 199.53M | P/E | - | EPS this Y | 18.30% | Ern Qtrly Grth | - |
Income | -117.86M | Forward P/E | -1.61 | EPS next Y | 9.10% | 50D Avg Chg | -24.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -38.00% |
Dividend | N/A | Price/Book | 0.87 | EPS next 5Y | - | 52W High Chg | -61.00% |
Recommedations | 1.60 | Quick Ratio | 8.81 | Shares Outstanding | 68.22M | 52W Low Chg | 13.00% |
Insider Own | 1.16% | ROA | -31.67% | Shares Float | 31.89M | Beta | -0.37 |
Inst Own | 88.57% | ROE | -58.74% | Shares Shorted/Prior | 3.39M/3.07M | Price | 2.98 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 220,090 | Target Price | 14.69 |
Oper. Margin | - | Earnings Date | May 9 | Volume | 114,562 | Change | -5.99% |
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Wedbush | Outperform | Apr 23, 24 |
JMP Securities | Market Outperform | Mar 22, 24 |
Stifel | Buy | Mar 21, 24 |
Wedbush | Outperform | Mar 21, 24 |
Oppenheimer | Outperform | Mar 21, 24 |
HC Wainwright & Co. | Buy | Mar 21, 24 |
Wedbush | Outperform | Jan 18, 24 |
JMP Securities | Market Outperform | Aug 14, 23 |
Wedbush | Outperform | Aug 11, 23 |